Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic Posts Revenue Gains, Narrowed Loss in Q3

NEW YORK, Oct. 28 - Gene Logic today said that an increase in GeneExpress subscribers helped boost third-quarter revenue by 23 percent. In addition, despite a boost in R&D spending and overall expenses, net loss in the quarter narrowed.


For the three-month period ended Sept. 30, Gene Logic reported $14.2 million in total receipts, up from $11.5 for the same quarter one year ago.


R&D spending in the quarter grew to $17.3 million from $14.5 million in the third quarter last year, and SG&A fell to $4.3 million in the current quarter from $4.7 million year over year, the company said.


Net loss narrowed during the third quarter to $7 million, or $.26 per share, from $7.2 million, or $.27 per share, year over year.


Gene Logic said it had roughly $171.9 million in cash and cash equivalents as of Sept. 30.


Click here for more information.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.